Showing results (401-410 of 561) with videos related to
Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.Molecular Cancer Therapeutics|July 3, 2019
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant CancersAdam Stewart, Elizabeth A Coker, Sebastian Pölsterl, et al.Heart (British Cardiac Society)|July 24, 2014
Device-dependent association between paravalvar aortic regurgitation and outcome after TAVIRafal Dworakowski, Olaf Wendler, Brian Halliday, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusEric Van Cutsem, Claus-Henning Köhne, István Láng, et al.Cell Reports|September 8, 2015
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXRLinara Gabitova, Diana Restifo, Andrey Gorin, et al.Journal of Lipid Research|December 8, 2009
Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infectionRonald W Clark, David Cunningham, Yang Cong, et al.International Journal of Cancer|June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsFrancesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Pageof 57